Viking Therapeutics, Inc. (VKTX) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped VKTX stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Viking Therapeutics (VKTX) represents one of the premier clinical-stage metabolic asset plays in modern biopharma. Currently trading near 52-week lows at $25.36 with a market capitalization of $3.0B, VKTX has suffered from retail frustration over launch timelines and earnings misses inherent to pre-revenue biotech companies. Despite near-term sentiment friction, the fundamental clinical asset value remains exceptionally potent. Wall Street consensus is unanimously bullish (21 Strong Buy ratings, median price target $95.00), implying greater than 260% upside. The company's dual GLP-1/GIP agonist, VK2735, has showcased top-tier weight-loss kinetics with manageable tolerability in both injectable and oral formats. As Viking transitions into pivotal Phase 3 programs and reports key oral trial updates, the risk-reward profile is skewed heavily to the upside, reinforced by persistent takeout optionality in an obesity market projected to surpass $100B. Downside risks center on clinical execution delays, dilution, and competitive crowding by Eli Lilly and Novo Nordisk. The saved 1-year distribution is P10 $16, P50 $42, and P90 $85.
Last analyzed · Model: gemini-3.8-flash
Viking Therapeutics, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $16 | Pessimistic plausible scenario |
| P50 | $42 | Median scenario |
| P90 | $85 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
VKTX trades at a steep discount ($25.36) relative to analyst consensus targets ($91.71 mean / $95.00 median), driven by near-term timeline friction and clinical trial burn. However, clinical Phase 3 progression for VK2735 subcutaneous and Phase 2 readouts for oral formulations provide massive upside optionality in a multi-billion dollar GLP-1/GIP market. Near-term volatility remains elevated due to quarterly net losses and capital needs.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this VKTX analysis generated?
October 29, 2026.
Is this a guaranteed VKTX prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full VKTX stock analysis · VKTX sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.